Daniel Zlott, PharmD, BCOP is the Senior Vice President of Education and Business Development at the American Pharmacists Association. Prior to joining APhA he worked as a Clinical Pharmacy Specialist with the U.S. National Cancer Institute’s Immunotherapy, Surgery, Endocrine Oncology, and Thoracic/GI Malignancy Branches at the U.S. National Institutes of Health (NIH). He was part of the team that developed the first Chimeric Antigen Receptor T-cell therapy given to treat B-cell cancers.
He was also the Director of the NIH PGY2 Oncology Pharmacy Residency Program and a clinical investigator on more than 40 NCI-sponsored clinical trials, examining new and innovative ways to treat cancer. Dr. Zlott has served two terms on the Board of Trustees of the American Pharmacists Association, and has also chaired numerous committees with the Hematology/Oncology Pharmacy Association.
He is a graduate of the University of California San Francisco and completed his PGY1 Pharmacy Practice Residency there before moving to the NIH, where he completed his PGY2 Oncology Pharmacy Residency.